quinazolines has been researched along with Carcinoma, Adenosquamous in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Q; Wu, L; Zhang, S | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Kieszko, R; Kowalski, DM; Krawczyk, KW; Krawczyk, P; Krzakowski, M; Milanowski, J; Mlak, R; Rolski, A; Szczyrek, M; Szudy, A; Winiarczyk, K | 1 |
| Barinow-Wojewódzki, A; Krawczyk, P; Kucharczyk, T; Milanowski, J; Milecki, P; Powrózek, T; Ramlau, R; Sura, S; Szumiło, J; Szyszka-Barth, K; Walczyna, B; Wojas-Krawczyk, K | 1 |
| Aoyama, A; Chen, F; Date, H; Menju, T; Omasa, M; Sato, M; Sato, T; Sonobe, M; Yamada, T; Yokoyama, Y | 1 |
| Kagohashi, K; Satoh, H; Tamura, T | 1 |
| Biagi, J; Cutz, JC; Dancey, J; Dore, N; Eisenhauer, EA; Elit, L; Fyles, A; Ghatage, P; Hoskins, PJ; Mazurka, J; Oza, AM; Provencher, D; Sakurada, A; Tsao, MS | 1 |
| Borgman, CL; Brandstetter, KA; Bronson, RT; Chen, L; Chesa, PG; Chirieac, LR; Greulich, H; Guertler, U; Ji, H; Kubo, S; Li, D; Meyerson, M; Padera, RF; Perera, SA; Raso, MG; Shapiro, GI; Shimamura, T; Solca, F; Takahashi, M; Wistuba, II; Wong, KK; Zaghlul, S | 1 |
| Bessho, A; Harita, S; Hayashi, H; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Umemura, S; Yoshioka, H | 1 |
| Eguchi, K; Fukuoka, M; Horai, T; Ichinose, Y; Masuda, N; Mitsudomi, T; Mori, K; Nukiwa, T; Saijo, N; Segawa, Y; Takahashi, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Iguchi, H; Ioka, T; Ito, T; Komatsu, Y; Nakachi, K; Nakagawa, K; Nakamori, S; Ohkawa, S; Okusaka, T; Yamao, K | 1 |
| Endo, M; Kaira, K; Kaira, R; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, K; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Goya, S; Hatazawa, J; Hirata, H; Inoue, A; Kawase, I; Kida, H; Kijima, T; Kumagai, T; Kumanogoh, A; Nagatomo, I; Okumura, M; Shimosegawa, E; Tachibana, I; Takahashi, R; Takeda, Y; Yoshida, M | 1 |
| Gemma, A; Gemmah, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kobayashi, K; Kudoh, S; Maemondo, M; Minegishi, Y; Morikawa, N; Nukiwa, T; Oizumi, S; Okinaga, S; Tanaka, T | 1 |
| Iwanaga, K; Kimura, S; Mori, D; Nakamura, T; Sueoka-Aragane, N | 1 |
| Chang, WC; Chen, YR; Chen, YT; Fu, YN; Huang, SF; Ku, YC; Kuo, HP; Li, LH; Lin, YF; Liu, HP; Tsai, HY; Tsai, SF; Wu, YC | 1 |
5 trial(s) available for quinazolines and Carcinoma, Adenosquamous
| Article | Year |
|---|---|
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Endometrial Neoplasms; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2008 |
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Adenosquamous; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2012 |
11 other study(ies) available for quinazolines and Carcinoma, Adenosquamous
| Article | Year |
|---|---|
Transformation of advanced lung adenocarcinoma to acquired T790M resistance mutation adenosquamous carcinoma following tyrosine kinase inhibitor: a case report.
Topics: Adenocarcinoma of Lung; Carcinoma, Adenosquamous; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2021 |
Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
EGFR gene mutations in patients with adenosquamous lung carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Poland; Polymerase Chain Reaction; Quinazolines; Remission Induction; Smoking | 2014 |
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Successful Afatinib Therapy after Resistance to EGFR-TKI in a Patient with Advanced Adenosquamous Cell Lung Cancer.
Topics: Afatinib; Aged; Carcinoma, Adenosquamous; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Lung Neoplasms; Mice; Mutation; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sirolimus | 2009 |
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2011 |
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2012 |
The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.
Topics: Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Adenosquamous; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Mutation, Missense; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2012 |
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Phosphorylation; Quinazolines; Sequence Homology, Nucleic Acid; Taiwan | 2004 |